PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
down 21%, driven by a negative impact from the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. Hospital products, which grew 10% operationally to $2.3 down 7%, which reflects relatively stable U.S. Chantix in the U.S., Source link.
40 
Let's personalize your content